This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Dec;14(13):1254-6.

doi: 10.1016/S1470-2045(13)70528-X. Epub 2013 Nov 15.

Can we improve ABVD in Hodgkin's lymphoma?

Christian Gisselbrecht¹

Affiliations

PMID: 24239219
DOI: 10.1016/S1470-2045(13)70528-X

Comment

Can we improve ABVD in Hodgkin's lymphoma?

Christian Gisselbrecht. Lancet Oncol. 2013 Dec.

. 2013 Dec;14(13):1254-6.

doi: 10.1016/S1470-2045(13)70528-X. Epub 2013 Nov 15.

Author

Christian Gisselbrecht¹

Affiliation

¹ Hopital Saint Louis, 1 Avenue Claude Vellefaux, Paris 7510, France. Electronic address: Christian.gisselbrecht@sls.aphp.fr.

PMID: 24239219
DOI: 10.1016/S1470-2045(13)70528-X

No abstract available

PubMed Disclaimer

Comment on

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Younes A, et al. Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15. Lancet Oncol. 2013. PMID: 24239220 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information